A full 14 years after founding CRO Clinipace, its longstanding CEO and president Jeff Williams is planning to step down.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.
Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.
Atlas Venture, Lightstone Ventures and OrbiMed put up the cash to equip Gemini to turn advances in our understanding of AMD genetics into a pipeline.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.
The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.